B. Riley initiated coverage of Radiopharm Theranostic (RADX) with a Buy rating and $15 price target Radiopharm in-licenses and incubates near-clinical-stage radiopharmaceutical assets for therapeutic and imaging purposes, the analyst tells investors in a research note. The firm believes the company’s clinical-stage pipeline is underappreciated by investors. Riley views RAD101 is well positioned to advance into a Phase III trial and be licensed out.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue